Johnson & Johnson (NYSE:JNJ) EVP Sells 33,597 Shares

Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Johnson & Johnson Stock Down 0.9%

Shares of JNJ traded down $2.52 during trading hours on Friday, reaching $275.91. 784,865 shares of the stock traded hands, compared to its average volume of 8,119,366. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The company has a market cap of $664.92 billion, a price-to-earnings ratio of 31.91, a PEG ratio of 2.63 and a beta of 0.24. The stock has a fifty day simple moving average of $261.57 and a 200 day simple moving average of $244.85. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the firm posted $2.77 EPS. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s payout ratio is currently 62.11%.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its position in shares of Johnson & Johnson by 25,103.8% in the second quarter. California State Teachers Retirement System now owns 943,488,645 shares of the company’s stock valued at $239,617,811,000 after acquiring an additional 939,745,213 shares during the period. State Street Corp grew its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after purchasing an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co increased its holdings in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after buying an additional 1,738,292 shares in the last quarter. Finally, Norges Bank purchased a new position in Johnson & Johnson during the fourth quarter worth about $6,924,523,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on JNJ shares. Bank of America lifted their target price on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research note on Friday, July 10th. The Goldman Sachs Group restated a “buy” rating and set a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $272.83.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: An analyst upgrade helped JNJ reach a new 12-month high, reinforcing investor confidence in the company’s defensive healthcare profile and growth prospects. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade
• Positive Sentiment: UBS raised its price target to $320, implying roughly 16% potential upside from recent levels. The higher target reflects stronger expectations for JNJ’s pharmaceutical pipeline, which could help offset upcoming product pressures. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: JNJ’s 64-year record of dividend increases remains a key attraction. The company’s diversified businesses and cash generation are viewed as supporting continued dividend growth even as Stelara faces intense competition. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Positive Sentiment: Analysts collectively maintain a “Moderate Buy” rating, suggesting that Wall Street still sees a favorable risk-reward balance despite the stock’s substantial appreciation. Johnson & Johnson Receives Average Rating of Moderate Buy

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.